Highlights Bellerophon Therapeutics, Inc. Börse Stuttgart

Equities

6L7A

US0787713009

Delayed Börse Stuttgart Other stock markets 11:31:13 13/10/2023 am IST			5-day change	1st Jan Change
0.421 ^EUR	+20.98%		+26.05%	-45.08%

02/05	North American Morning Briefing : Stock Futures -2-	DJ
25/04	North American Morning Briefing : More Tech -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stocks Set for -2-	28/03	DJ
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Bellerophon Therapeutics, Inc. Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease	05/23/05	CI
Bellerophon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Bellerophon Therapeutics, Inc. Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease	11/23/11	CI
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
Bellerophon Therapeutics, Inc. Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse(R) in Fibrotic Interstitial Lung Disease	09/23/09	CI
Bellerophon Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease	19/23/19	CI
Bellerophon Therapeutics Secures Licensing Deal With Baylor BioSciences for INOpulse in China; Shares Surge 200%	05/23/05	MT
Bellerophon Therapeutics, Inc. Announces License Agreement for the Commercialization of INOpulse(R) in Greater China with Baylor BioSciences	05/23/05	CI
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Bellerophon Provides Clinical Program Update	14/22/14	CI
Bellerophon Therapeutics' New Phase 3 Trial Size for Lung Disorder Drug Gets US FDA Nod; Shares Rise	27/22/27	MT
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 Rebuild Study of Inopulse for Treatment of Fibrotic Interstitial Lung Disease	27/22/27	CI
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/22/15	CI
Bellerophon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	11/22/11	CI
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	01/22/01	CI
Bellerophon Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of Inopulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis	17/21/17	CI
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/21/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Bellerophon Therapeutics, Inc. Börse Stuttgart

Equities

6L7A

US0787713009

Highlights

Filters